# Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

> **NCT05008055** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Capivasertib

## Key facts

- **NCT ID:** NCT05008055
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-03
- **Primary completion:** 2023-08-22
- **Final completion:** 2024-10-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05008055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05008055, "Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05008055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*